<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40029">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01698723</url>
  </required_header>
  <id_info>
    <org_study_id>HEV-RIBA</org_study_id>
    <nct_id>NCT01698723</nct_id>
  </id_info>
  <brief_title>A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus</brief_title>
  <acronym>HEVRibavirin</acronym>
  <official_title>A Double Blind Placebo Controlled Randomized Trial of Ribavirin in Patients With Acute on Chronic Liver Failure Due to Hepatitis E Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, New Delhi</source>
  <oversight_info>
    <authority>India: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The term Acute on chronic liver failure (ACLF) describes a clinical entity characterized by
      an acute and rapid deterioration of liver function in a patient with previously
      well-compensated liver disease owing to the effects of a precipitating event. In this
      condition two insults act simultaneously, one being the preexisting liver injury (chronic
      liver disease) and the other acute injury which is responsible for the acute decompensation.
      HEV being a major factor responsible for this clinical entity and has a very high mortality
      rate. Ribavirin being a safe drug and has been shown to inhibit the replication of HEV, can
      be an important drug in the treatment of these patients. Therefore the present study is
      designed to study the impact of Ribavirin in reducing the mortality due to HEV related ACLF.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement in survival</measure>
    <time_frame>4 weeks and 12 moths</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Child Score</measure>
    <time_frame>4 weeks and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change in Child Score will be evaluated at every 4 week interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viremia</measure>
    <time_frame>4 weeks, 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variceal bleeding</measure>
    <time_frame>4 weeks and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Variceal bleeding will be assessed every 4 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute on Chronic Hepatic Failure</condition>
  <condition>Liver Failure</condition>
  <condition>Hepatitis E Infection</condition>
  <arm_group>
    <arm_group_label>Ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mg (5 capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 capsules of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All ACLF due to HEV

          -  Consent to participate in trial and collection of blood.

        Exclusion Criteria:

          -  Pregnant and nursing mothers.

          -  Severe anemia

          -  Other etiologies of ACLF (eg. Alcohol, drugs, reactivation of hepatitis B     and
             hepatitis C, variceal bleeding, surgical intervention and sepsis)

          -  Hepatocellular carcinoma (HCC)

          -  Hepatorenal syndrome (HRS) at admission

          -  Presence of life threatening cardiovascular, respiratory and neurological disease

          -  Acquired Immunodeficiency Syndrome

          -  Patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia)

          -  Refusal to provide consent to participate in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Subrat K Acharya, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Subrat K Acharya, DM</last_name>
    <phone>+91-11-26594934</phone>
    <email>subratacharya2004@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shalimar ., DM</last_name>
    <phone>+919968405815</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AII India Institute of Medical Sciences</name>
      <address>
        <city>Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subrat K Acharya, DM</last_name>
      <phone>+91-11-26594934</phone>
      <email>subratacharya2004@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Shalimar ., DM</last_name>
      <phone>+91-9968405815</phone>
      <email>drshalimar@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Subrat K Acharya, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subrat K Acharya, DM</last_name>
      <phone>+91-11-26594934</phone>
      <email>subratacharya2004@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Shalimar ., DM</last_name>
      <phone>+91-9968405815</phone>
      <email>drshalimar@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Subrat K Acharya, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 29, 2012</lastchanged_date>
  <firstreceived_date>September 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, New Delhi</investigator_affiliation>
    <investigator_full_name>Subrat Kumar Acharya</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ACLF</keyword>
  <keyword>HEV</keyword>
  <keyword>Ribavirin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis E</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
